Literature DB >> 23148060

Corticosteroid therapy in acute respiratory distress syndrome.

François Lamontagne1, Roy Brower, Maureen Meade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23148060      PMCID： PMC3576439          DOI： 10.1503/cmaj.120582

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  50 in total

1.  A comparison of in vitro bioassays to determine cellular glucocorticoid sensitivity.

Authors:  H Vermeer; B I Hendriks-Stegeman; A A Verrijn Stuart; S C van Buul-Offers; M Jansen
Journal:  Eur J Endocrinol       Date:  2004-01       Impact factor: 6.664

2.  An in vitro bioassay to determine individual sensitivity to glucocorticoids: induction of FKBP51 mRNA in peripheral blood mononuclear cells.

Authors:  Harry Vermeer; Brenda I Hendriks-Stegeman; Denise van Suylekom; Ger T Rijkers; Sylvia C van Buul-Offers; Maarten Jansen
Journal:  Mol Cell Endocrinol       Date:  2004-04-15       Impact factor: 4.102

Review 3.  Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials.

Authors:  François Lamontagne; Matthias Briel; Gordon H Guyatt; Deborah J Cook; Neera Bhatnagar; Maureen Meade
Journal:  J Crit Care       Date:  2009-11-05       Impact factor: 3.425

4.  Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome.

Authors: 
Journal:  Crit Care Med       Date:  2002-01       Impact factor: 7.598

5.  Wide variation in lymphocyte steroid sensitivity among healthy human volunteers.

Authors:  S D Hearing; M Norman; C Smyth; C Foy; C M Dayan
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

6.  Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids.

Authors:  G Umberto Meduri; Elizabeth A Tolley; George P Chrousos; Frankie Stentz
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

7.  Effect of corticosteroid on lung parenchyma remodeling at an early phase of acute lung injury.

Authors:  Patricia R M Rocco; Alba B Souza; Debora S Faffe; Caroline P Pássaro; Flávia B Santos; Elnara M Negri; Januário G M Lima; Renata S Contador; Vera L Capelozzi; Walter A Zin
Journal:  Am J Respir Crit Care Med       Date:  2003-07-03       Impact factor: 21.405

8.  Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production.

Authors:  Roel H DeRijk; Farideh Eskandari; Esther M Sternberg
Journal:  J Neuroimmunol       Date:  2004-06       Impact factor: 3.478

Review 9.  Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS.

Authors:  G Umberto Meduri; Charles R Yates
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

10.  Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability.

Authors:  Harry Vermeer; Brenda I Hendriks-Stegeman; Bart van der Burg; Sylvia C van Buul-Offers; Maarten Jansen
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958
View more
  3 in total

1.  Biology and pathology of fibroproliferation following the acute respiratory distress syndrome.

Authors:  Carolyn M Hendrickson; Bruno Crestani; Michael A Matthay
Journal:  Intensive Care Med       Date:  2014-12-06       Impact factor: 17.440

Review 2.  New Insights into the Immune Molecular Regulation of the Pathogenesis of Acute Respiratory Distress Syndrome.

Authors:  Chin-Yao Yang; Chien-Sheng Chen; Giou-Teng Yiang; Yeung-Leung Cheng; Su-Boon Yong; Meng-Yu Wu; Chia-Jung Li
Journal:  Int J Mol Sci       Date:  2018-02-16       Impact factor: 5.923

3.  Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils.

Authors:  Jesus Banuelos; Yun Cao; Soon Cheon Shin; Bruce S Bochner; Pedro Avila; Shihong Li; Xin Jiang; Mark W Lingen; Robert P Schleimer; Nick Z Lu
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.